Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma (FIZZ)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Bayer
Information provided by:
Christie Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01493479
First received: December 14, 2011
Last updated: December 15, 2011
Last verified: December 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2015
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
No publications provided by Christie Hospital NHS Foundation Trust

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):